Acrivon Therapeutics, Inc. (ACRV)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.46
- As of
Kresmion compiles this page from ACRV's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Acrivon Therapeutics, Inc. (ACRV): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-16.
See the full ACRV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ACRV on one page. Preview it with sample data, then open it live with a free account.
Preview the ACRV dossierActive events for ACRV
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 86% of ACRV (2026Q3)
- high13F: large reduction
CITADEL ADVISORS LLC cut 59% of ACRV (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +65% to ACRV (2026Q2)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 8.0% - EPS $-0.55 vs $-0.598 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 21.9% - EPS $-0.47 vs $-0.6018 estimate
FREE, NO ACCOUNT
Every event on ACRV, as it fires
You are seeing 5 of 7 events recorded on ACRV since 2026-06-21.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ACRV positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 004890109 · 2026Q3 | $213K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACRV
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
Going concern statement
ACRV's 10-Q filed Nov 16, 2026 states:
…and existing cash, cash 8 equivalents, and investments, the Company has determined that there is substantial doubt regarding its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on ACRV
ACRV against its peers
ACRV's return on equity of -69.2% ranks in the 47th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | ACRV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 7.9M | n/a | 13 |
| Gross margin | n/a | 66.9% | n/a | 5 |
| Operating margin | n/a | -251.6% | n/a | 12 |
| Net margin | n/a | -267.1% | n/a | 13 |
| Return on equity | -69.2% | -68.5% | 47 | 17 |
| 1 year | -38.1% | -45.0% | 55 | 20 |
Peers (22): NTRB, CSBR, NRXS, CING, MNOV, GOSS, MAIA, CRBP, MIST, COYA, SMNR, RANI, CRDF, FBIO, TENX, OKYO, CGTX, XBIT, KZIA, HRTX, SPRO, ATRA. Left out: CNXU (no annual filing), TLSA (period gap), TNXP (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (ACRV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ACRV on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ACRV in the last 180 days.
Upstream: SEC EDGAR filings for ACRV
Kresmion, "Acrivon Therapeutics, Inc. (ACRV) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/ACRV. Upstream data: SEC EDGAR filings for ACRV.
Link to this data (HTML):
<a href="https://kresmion.com/research/ACRV">Acrivon Therapeutics, Inc. (ACRV) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ACRV on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ACRV for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.